March 24, 2023

Expert Point of View: Xin Gao, MD

Dr. Xin Gao from Harvard Medical School shares new insights on sacituzumab govitecan's efficacy in metastatic urothelial cancer patients and examines future research prospects.

The ASCO Post

July 11, 2024

Association of Genetic Risk for Prostate Cancer With Early Prostate Cancer Death

A recent cohort study found that men at a higher genetic risk for prostate cancer were more likely to experience early death from prostate cancer compared to men with a lower genetic risk for the dise...

The ASCO Post

February 20, 2023

Nivolumab After Surgical Resection Improves Disease-Free Survival for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma

Adjuvant therapy with the immune checkpoint inhibitor nivolumab following surgery improved disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma, according to new findi...

The ASCO Post

April 09, 2025

Prostate Cancer: Biomarker Test May Predict GU Toxicity From SBRT

Researchers have validated a biomarker test for predicting the development of genitourinary adverse effects induced by stereotactic body radiotherapy (SBRT) in patients with prostate cancer, according...

The ASCO Post

February 20, 2023

Single-Arm Phase II Noninferiority Trial Evaluates Active Surveillance vs Cystectomy Following Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Carcinoma

Researchers have found that following chemotherapy, 46% of patients with muscle-invasive urothelial carcinoma were able to avoid a cystectomy and achieve a 2-year metastasis-free survival, according t...

The ASCO Post

February 06, 2025

Results From FIRE-4 Show Liquid Biopsy Can Detect RAS/BRAF-Mutated Metastatic Colorectal Cancer

The results from the phase III FIRE-4 randomized clinical trial showed that liquid biopsy accurately identified patients with RAS/BRAF V600E wild type-mutated metastatic colorectal cancer. These findi...

The ASCO Post

March 05, 2024

Metastatic Castration-Resistant Prostate Cancer: Tumor Mutational Burden and Response to Checkpoint Inhibition

Is high tumor mutational burden associated with better outcomes of checkpoint inhibition in patients with metastatic castration-resistant prostate cancer? A recent single-center retrospective study in...

The ASCO Post

February 07, 2024

Insufficiencies Discovered in Patient-Reported Outcomes Data From Genitourinary Cancer Clinical Trials

Investigators assessed whether patient-reported outcomes data are adequately analyzed and reported in genitourinary cancer clinical trials.

The ASCO Post

January 30, 2024

Subcutaneous vs Intravenous Nivolumab in Advanced Clear Cell RCC

In previously treated patients with advanced or metastatic clear cell renal cell carcinoma, a subcutaneous formulation of nivolumab was noninferior to the intravenous formulation, according to results...

The ASCO Post